<p>摩根大通降低了其在 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）股票中的持股比例，第四季度持股下降了 71.5%，根據其最近向證券交易委員會提交的 13F 表格。該機構投資者在本季度出售了 385,349 股後，持有 153,571 股該公司的股票。截至最近報告期末，摩根大通持有的 Amphastar Pharmaceuticals 的股份約佔 0.32%，價值 5,702,000 美元。</p>
<ul>
<li>在降息前值得購買的前兩隻小型醫療股</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也增加或減少了對 AMPH 的持股。Pacer Advisors Inc.在第四季度將其在 Amphastar Pharmaceuticals 的持股比例提高了 51,977.4%。Pacer Advisors Inc.現在持有 1,350,368 股該公司的股票，價值 50,139,000 美元，此前在上個季度又購買了 1,347,775 股。Boston Trust Walden Corp 在第四季度將其在 Amphastar Pharmaceuticals 的持股比例提高了 81.4%。Boston Trust Walden Corp 現在持有 978,920 股該公司的股票，價值 36,347,000 美元，此前在上個季度又購買了 439,281 股。Boston Partners 在第四季度購買了價值約 15,778,000 美元的 Amphastar Pharmaceuticals 新股份。Wealthfront Advisers LLC 在第四季度購買了價值 9,268,000 美元的 Amphastar Pharmaceuticals 新股份。最後，Raymond James Financial Inc.在第四季度購買了價值 3,450,000 美元的 Amphastar Pharmaceuticals 新股份。機構投資者持有該公司 65.09% 的股票。</p>
<h2>Amphastar Pharmaceuticals 的內部買賣</h2>
<p>在相關消息中，首席財務官 William J. Peters 於 3 月 4 日星期二出售了 4,231 股 Amphastar Pharmaceuticals 的股票。該股票以 27.54 美元的平均價格出售，總價值為 116,521.74 美元。交易完成後，首席財務官現在直接持有 97,363 股該公司的股票，價值約為 2,681,377.02 美元。這筆交易代表了他們持有股票的比例減少了 4.16%。該交易已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。27.10% 的股票由內部人士持有。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>有前景的小型生物技術公司 Amphastar 經歷了可操作的回調</li>
</ul>
<p>幾位研究分析師最近對 AMPH 股票發表了看法。Piper Sandler 將 Amphastar Pharmaceuticals 的目標價從 36.00 美元下調至 32.00 美元，並在 3 月 21 日的研究報告中對該股票給予了 “中性” 評級。Needham &amp; Company LLC 在 4 月 10 日的研究報告中重申了對 Amphastar Pharmaceuticals 股票的 “持有” 評級。</p>
<p><strong>閲讀我們最新的 AMPH 股票分析</strong></p>
<h2>Amphastar Pharmaceuticals 股票上漲 1.6%</h2>
<p>AMPH 的股票在週五開盤價為 23.35 美元。該股票的 50 日移動平均價格為 27.78 美元，200 日移動平均價格為 37.36 美元。Amphastar Pharmaceuticals, Inc.的 52 周最低價為 22.64 美元，最高價為 53.96 美元。該公司的市值為 11.1 億美元，市盈率為 7.78，PEG 比率為 2.19，貝塔值為 0.79。該公司的速動比率為 2.61，流動比率為 3.43，債務與股本比率為 0.82。</p>
<h2>Amphastar Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Amphastar Pharmaceuticals, Inc.是一家生物製藥公司，在美國、中國和法國開發、生產、營銷和銷售仿製藥和專有的注射、吸入和鼻用產品。它提供 BAQSIMI，一種用於治療嚴重低血糖的鼻用噴霧劑；Primatene Mist，一種用於暫時緩解間歇性哮喘輕微症狀的非處方腎上腺素吸入產品；Enoxaparin，用於預防和治療深靜脈血栓；REXTOVY 和 Naloxone 用於阿片類藥物過量；用於緊急情況的胰高血糖素注射套件；以及 Cortrosyn，用作篩查腎上腺皮質功能不全患者的診斷劑。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票超過 Amphastar Pharmaceuticals</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>3 只中型到大型股票宣佈了重大回購</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>這 3 只股票在過去 12 個月中為股東帶來了巨大的收益</li>
<li>成長股：它們是什麼，示例及如何投資</li>
<li>知名對沖基金收購 HPE 的巨大股份：現在值得購買嗎？</li>
</ul>
<p><strong>想看看其他對沖基金持有的 AMPH 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Amphastar Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Amphastar Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就購買，以便在更廣泛的市場注意到之前……而 Amphastar Pharmaceuticals 並不在名單上。</p>
<p>雖然 Amphastar Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

摩根大通

Amphastar制藥

<p>摩根大通已將其在 Amphastar Pharmaceuticals, Inc.（納斯達克代碼：AMPH）的持股減少了 71.5%，在第四季度出售了 385,349 股，剩餘持有 153,571 股，價值約為 570 萬美元。其他機構投資者也調整了他們的持股，Pacer Advisors Inc.顯著增加了其持股。該股票開盤價為 23.35 美元，52 周區間為 22.64 美元至 53.96 美元。分析師們設定了新的價格目標，Piper Sandler 將其目標從 36.00 美元下調至 32.00 美元，並維持 “中性” 評級</p>

<p>JPMorgan Chase &amp; Co. lowered its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 71.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,571 shares of the company's stock after selling 385,349 shares during the quarter. JPMorgan Chase &amp; Co. owned approximately 0.32% of Amphastar Pharmaceuticals worth $5,702,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>摩根大通降低了其在 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）股票中的持股比例，第四季度持股下降了 71.5%，根據其最近向證券交易委員會提交的 13F 表格。該機構投資者在本季度出售了 385,349 股後，持有 153,571 股該公司的股票。截至最近報告期末，摩根大通持有的 Amphastar Pharmaceuticals 的股份約佔 0.32%，價值 5,702,000 美元。</p>
</div><ul>
<li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在降息前值得購買的前兩隻小型醫療股</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMPH. Pacer Advisors Inc. lifted its stake in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp grew its stake in shares of Amphastar Pharmaceuticals by 81.4% during the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after buying an additional 439,281 shares during the last quarter. Boston Partners bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at approximately $15,778,000. Wealthfront Advisers LLC purchased a new position in Amphastar Pharmaceuticals during the 4th quarter worth $9,268,000. Finally, Raymond James Financial Inc. bought a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at $3,450,000. Institutional investors own 65.09% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也增加或減少了對 AMPH 的持股。Pacer Advisors Inc.在第四季度將其在 Amphastar Pharmaceuticals 的持股比例提高了 51,977.4%。Pacer Advisors Inc.現在持有 1,350,368 股該公司的股票，價值 50,139,000 美元，此前在上個季度又購買了 1,347,775 股。Boston Trust Walden Corp 在第四季度將其在 Amphastar Pharmaceuticals 的持股比例提高了 81.4%。Boston Trust Walden Corp 現在持有 978,920 股該公司的股票，價值 36,347,000 美元，此前在上個季度又購買了 439,281 股。Boston Partners 在第四季度購買了價值約 15,778,000 美元的 Amphastar Pharmaceuticals 新股份。Wealthfront Advisers LLC 在第四季度購買了價值 9,268,000 美元的 Amphastar Pharmaceuticals 新股份。最後，Raymond James Financial Inc.在第四季度購買了價值 3,450,000 美元的 Amphastar Pharmaceuticals 新股份。機構投資者持有該公司 65.09% 的股票。</p>
</div><h2>Insider Buying and Selling at Amphastar Pharmaceuticals</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 的內部買賣</h2>
</div><p>In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.10% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 William J. Peters 於 3 月 4 日星期二出售了 4,231 股 Amphastar Pharmaceuticals 的股票。該股票以 27.54 美元的平均價格出售，總價值為 116,521.74 美元。交易完成後，首席財務官現在直接持有 97,363 股該公司的股票，價值約為 2,681,377.02 美元。這筆交易代表了他們持有股票的比例減少了 4.16%。該交易已在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。27.10% 的股票由內部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>Promising Small Biotech Amphastar Sees Actionable Pullback</li>
</ul>
<div class="lb-trans"><ul>
<li>有前景的小型生物技術公司 Amphastar 經歷了可操作的回調</li>
</ul>
</div><p>Several research analysts recently weighed in on AMPH shares. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, March 21st. Needham &amp; Company LLC restated a &#34;hold&#34; rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 AMPH 股票發表了看法。Piper Sandler 將 Amphastar Pharmaceuticals 的目標價從 36.00 美元下調至 32.00 美元，並在 3 月 21 日的研究報告中對該股票給予了 “中性” 評級。Needham &amp; Company LLC 在 4 月 10 日的研究報告中重申了對 Amphastar Pharmaceuticals 股票的 “持有” 評級。</p>
</div><p><strong>Read Our Latest Stock Analysis on AMPH</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 AMPH 股票分析</strong></p>
</div><h2>Amphastar Pharmaceuticals Stock Up 1.6 %</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 股票上漲 1.6%</h2>
</div><p>Shares of AMPH opened at $23.35 on Friday. The stock's 50-day moving average price is $27.78 and its 200-day moving average price is $37.36. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 7.78, a PEG ratio of 2.19 and a beta of 0.79. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.</p>
<div class="lb-trans"><p>AMPH 的股票在週五開盤價為 23.35 美元。該股票的 50 日移動平均價格為 27.78 美元，200 日移動平均價格為 37.36 美元。Amphastar Pharmaceuticals, Inc.的 52 周最低價為 22.64 美元，最高價為 53.96 美元。該公司的市值為 11.1 億美元，市盈率為 7.78，PEG 比率為 2.19，貝塔值為 0.79。該公司的速動比率為 2.61，流動比率為 3.43，債務與股本比率為 0.82。</p>
</div><h2>Amphastar Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals, Inc.是一家生物製藥公司，在美國、中國和法國開發、生產、營銷和銷售仿製藥和專有的注射、吸入和鼻用產品。它提供 BAQSIMI，一種用於治療嚴重低血糖的鼻用噴霧劑；Primatene Mist，一種用於暫時緩解間歇性哮喘輕微症狀的非處方腎上腺素吸入產品；Enoxaparin，用於預防和治療深靜脈血栓；REXTOVY 和 Naloxone 用於阿片類藥物過量；用於緊急情況的胰高血糖素注射套件；以及 Cortrosyn，用作篩查腎上腺皮質功能不全患者的診斷劑。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Amphastar Pharmaceuticals</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>These 3 Stocks Have Huge Last 12 Months Shareholder Yields</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Amphastar Pharmaceuticals</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>3 只中型到大型股票宣佈了重大回購</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>這 3 只股票在過去 12 個月中為股東帶來了巨大的收益</li>
<li>成長股：它們是什麼，示例及如何投資</li>
<li>知名對沖基金收購 HPE 的巨大股份：現在值得購買嗎？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMPH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 AMPH 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Amphastar Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Amphastar Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就購買，以便在更廣泛的市場注意到之前……而 Amphastar Pharmaceuticals 並不在名單上。</p>
</div><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amphastar Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

摩根大通出售了 385,349 股 Amphastar 製藥公司（NASDAQ:AMPH）的股份